



Datasheet for ABIN3042480
anti-RIPK1 antibody (AA 316-671)



[Go to Product page](#)

2 Images

2 Publications

Overview

Quantity:	100 µg
Target:	RIPK1
Binding Specificity:	AA 316-671
Reactivity:	Human
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This RIPK1 antibody is un-conjugated
Application:	Western Blotting (WB)

Product Details

Purpose:	Rabbit IgG polyclonal antibody for Receptor-interacting serine/threonine-protein kinase 1(RIPK1) detection. Tested with WB in Human.
Immunogen:	E.coli-derived human RIP recombinant protein (Position: K316-N671). Human RIP shares 65% amino acid (aa) sequence identity with mouse RIP.
Isotype:	IgG
Cross-Reactivity (Details):	No cross reactivity with other proteins.
Characteristics:	Rabbit IgG polyclonal antibody for Receptor-interacting serine/threonine-protein kinase 1(RIPK1) detection. Tested with WB in Human. Gene Name: receptor (TNFRSF)-interacting serine-threonine kinase 1 Protein Name: Receptor-interacting serine/threonine-protein kinase 1
Purification:	Immunogen affinity purified.

Target Details

Target: RIPK1

Alternative Name: RIPK1 ([RIPK1 Products](#))

Background: RIPK1, also known as RIP or RIP1, is an enzyme that in humans is encoded by the RIPK1 gene. It is mapped to 6p25.2. RIPK1 is a key signaling molecule in the programmed necrosis pathway, which plays important roles in development, tissue damage response, and antiviral immunity. RIPK1 is known to have function in a variety of cellular pathways including the NF- κ B pathway and programmed necrotic cell death (necroptosis). The kinase domain, while important for necroptotic (programmed necrotic) functions, it appears dispensable for other lethal, as well as pro-survival roles. Also, proteolytic processing of RIPK1, through both caspase-dependent and -independent mechanisms, triggers lethality that is dependent on the generation of one or more specific C-terminal cleavage product(s) of RIPK1 upon stress.

Synonyms: Cell death protein RIP antibody|FLJ39204 antibody|OTTHUMP00000039163 antibody|Receptor (TNFRSF) interacting serine threonine kinase 1 antibody|receptor interacting protein 1 antibody|Receptor interacting protein antibody|Receptor interacting serine threonine protein kinase 1 antibody|Receptor TNFRSF interacting serine threonine kinase 1 antibody|Receptor-interacting protein 1 antibody|Receptor-interacting serine/threonine-protein kinase 1 antibody|Rinp antibody|RIP 1 antibody|RIP antibody|Rip-1 antibody|RIP1 antibody|RIPK 1 antibody|Ripk1 antibody|RIPK1_HUMAN antibody|Serine threonine protein kinase RIP antibody|Serine/threonine-protein kinase RIP antibody

Gene ID: 8737

UniProt: [Q13546](#)

Pathways: [NF-kappaB Signaling](#), [Apoptosis](#), [Caspase Cascade in Apoptosis](#), [TLR Signaling](#), [Activation of Innate immune Response](#), [Inositol Metabolic Process](#), [Positive Regulation of Endopeptidase Activity](#), [Hepatitis C](#), [Protein targeting to Nucleus](#), [Toll-Like Receptors Cascades](#), [Negative Regulation of intrinsic apoptotic Signaling](#), [SARS-CoV-2 Protein Interactome](#), [Ubiquitin Proteasome Pathway](#)

Application Details

Application Notes: WB: Concentration: 0.1-0.5 μ g/mL, Tested Species: Human, The detection limit for RIP is approximately 0.25 ng/lane under reducing conditions.

Notes: Tested Species: Species with positive results.

Other applications have not been tested. Optimal dilutions should be determined by end users.

Application Details

Comment: Antibody can be supported by chemiluminescence kit ABIN921124 in WB.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Add 0.2 mL of distilled water will yield a concentration of 500 µg/mL.

Concentration: 500 µg/mL

Buffer: Each vial contains 5 mg BSA, 0.9 mg NaCl, 0.2 mg Na₂HPO₄, 0.05 mg Sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: At -20°C for one year. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20 °C for a longer time. Avoid repeated freezing and thawing.

Publications

Product cited in: Zhang, Wu: "Fasudil inhibits proliferation and migration of Hep-2 laryngeal carcinoma cells." in: **Drug design, development and therapy**, Vol. 12, pp. 373-381, (2018) ([PubMed](#)).

Zhou, Wu, Ma, Xiao, Yu, Yang, Xu, Zhang, Zhou, Ye, Wang: "Attenuation of TGFBR2 expression and tumour progression in prostate cancer involve diverse hypoxia-regulated pathways." in: **Journal of experimental & clinical cancer research : CR**, Vol. 37, Issue 1, pp. 89, (2018) ([PubMed](#)).


Schwartz, Bochkariov: "Novel chemiluminescent Western blot blocking and antibody incubation solution for enhanced antibody-antigen interaction and increased specificity." in: **Electrophoresis**, Vol. 38, Issue 20, pp. 2631-2637, (2017) ([PubMed](#)).

Zuo, Liu, Zhang, Wu, Guo, Liao: "Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance." in: **Scientific reports**, Vol. 5, pp.

11634, (2015) ([PubMed](#)).

Chen, Bao, Zhou, Wang, Wei, Fan: "Glucose transporter-1 expression in CD133+ laryngeal carcinoma Hep-2 cells." in: **Molecular medicine reports**, Vol. 8, Issue 6, pp. 1695-700, (2013) ([PubMed](#)).

Images



Western Blotting

Image 1. Anti-RIP Picoband antibody, All lanes: Anti RIP at 0.5ug/ml WB: Recombinant Human RIP Protein 0.5ng Predicted bind size: 38KD Observed bind size: 38KD

Western Blotting

Image 2. Observed bind size: 76KD